Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment

View ORCID ProfileHélène E. Aschmann, View ORCID ProfileAllan Musinguzi, View ORCID ProfileJillian L. Kadota, Catherine Namale, Juliet Kakeeto, Jane Nakimuli, Lydia Akello, Fred Welishe, Anne Nakitende, Christopher Berger, David W. Dowdy, View ORCID ProfileAdithya Cattamanchi, Fred C. Semitala, View ORCID ProfileAndrew D. Kerkhoff
doi: https://doi.org/10.1101/2023.09.13.23295043
Hélène E. Aschmann
1Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA USA
2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA USA
3Center for Tuberculosis, University of California San Francisco, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hélène E. Aschmann
  • For correspondence: helene.aschmann{at}ucsf.edu
Allan Musinguzi
4Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Allan Musinguzi
Jillian L. Kadota
1Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA USA
3Center for Tuberculosis, University of California San Francisco, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jillian L. Kadota
Catherine Namale
5Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliet Kakeeto
5Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Nakimuli
4Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lydia Akello
4Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Welishe
4Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Nakitende
4Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Berger
1Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA USA
3Center for Tuberculosis, University of California San Francisco, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Dowdy
5Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda
6Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adithya Cattamanchi
3Center for Tuberculosis, University of California San Francisco, San Francisco, CA USA
5Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda
7Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adithya Cattamanchi
Fred C. Semitala
4Infectious Diseases Research Collaboration, Kampala, Uganda
8Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
9Makerere University Joint AIDS Program, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew D. Kerkhoff
3Center for Tuberculosis, University of California San Francisco, San Francisco, CA USA
10Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew D. Kerkhoff
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens.

Methods We conducted a discrete choice experiment among adult PLHIV engaged in care at an urban HIV clinic in Kampala, Uganda. In nine random choice tasks, participants chose between two hypothetical TPT regimens with different features (pills per dose, frequency, duration, need for adjusted antiretroviral therapy [ART] dosage and side effects). We analyzed preferences using hierarchical Bayesian estimation, latent class analysis, and willingness-to-trade simulations.

Results Of 400 PLHIV, 392 (median age 44, 72% female, 91% TPT-experienced) had high quality choice task responses. Pills per dose was the most important attribute (relative importance 32.4%, 95% confidence interval [CI] 31.6 – 33.2), followed by frequency (20.5% [95% CI 19.7 – 21.3]), duration (19.5% [95% CI 18.6 – 20.5]), and need for ART dosage adjustment (18.2% [95% CI 17.2 – 19.2]). Latent class analysis identified three preference groups: one prioritized less frequent, weekly dosing (N=222; 57%); another was averse to ART dosage adjustment (N=107; 27%); and the last prioritized short and tolerable regimens (N=63; 16%). All groups highly valued fewer pills per dose. Participants were willing to accept a regimen of 2.8 months’ additional duration [95% CI: 2.4 – 3.2] to reduce pills per dose from five to one, 3.6 [95% CI 2.4 – 4.8] months for weekly rather than daily dosing, and 2.2 [95% CI 1.3 – 3.0] months to avoid ART dosage adjustment.

Conclusions To align with preferences of PLHIV, decision-makers should prioritize the development and implementation of TPT regimens with fewer pills, less frequent dosing, and no need for ART dosage adjustment, rather than focus primarily on duration of treatment.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by grants from the National Heart, Lung and Blood Institute (R01HL144406, AC and DWD) and National Institute of Allergy and Infectious Diseases (K23AI157914, ADK) of the National Institutes of Health, and by Early Postdoc.Mobility (191414, HEA) and Postdoc.Mobility (214129, HEA) fellowships from the Swiss National Science Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Makerere School of Public Health Research and Ethics Committee (SPH-2022-231), the University of San Francisco Institutional Review Board (22-36079) and the Uganda National Council for Science and Technology (HS2261ES) approved the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 14, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment
Hélène E. Aschmann, Allan Musinguzi, Jillian L. Kadota, Catherine Namale, Juliet Kakeeto, Jane Nakimuli, Lydia Akello, Fred Welishe, Anne Nakitende, Christopher Berger, David W. Dowdy, Adithya Cattamanchi, Fred C. Semitala, Andrew D. Kerkhoff
medRxiv 2023.09.13.23295043; doi: https://doi.org/10.1101/2023.09.13.23295043
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment
Hélène E. Aschmann, Allan Musinguzi, Jillian L. Kadota, Catherine Namale, Juliet Kakeeto, Jane Nakimuli, Lydia Akello, Fred Welishe, Anne Nakitende, Christopher Berger, David W. Dowdy, Adithya Cattamanchi, Fred C. Semitala, Andrew D. Kerkhoff
medRxiv 2023.09.13.23295043; doi: https://doi.org/10.1101/2023.09.13.23295043

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)